Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review)

MICHAL ZUZČÁK¹,² and JAN TRNKA¹,²

¹Department of Biochemistry, Cell and Molecular Biology, and ²Center for Research on Nutrition, Metabolism and Diabetes, Third Faculty of Medicine, Charles University, 10000 Prague, Czech Republic

Received March 3, 2022; Accepted May 10, 2022

DOI: 10.3892/ijo.2022.5383

Abstract. Pancreatic cancer (PC) has one of the highest fatality rates and the currently available therapeutic options are not sufficient to improve its overall poor prognosis. In addition to insufficient effectiveness of anticancer treatments, the lack of clear early symptoms and early metastatic spread maintain the PC survival rates at a low level. Metabolic reprogramming is among the hallmarks of cancer and could be exploited for the diagnosis and treatment of PC. PC is characterized by its heterogeneity and, apart from molecular subtypes, the identification of metabolic subtypes in PC could aid in the development of more individualized therapeutic approaches and may lead to improved clinical outcomes. In addition to the deregulated utilization of glucose in aerobic glycolysis, PC cells can use a wide range of substrates, including branched-chain amino acids, glutamine and lipids to fulfill their energy requirements, as well as biosynthetic needs. The tumor microenvironment in PC supports tumor growth, metastatic spread, treatment resistance and the suppression of the host immune response. Moreover, reciprocal interactions between cancer and stromal cells enhance their metabolic reprogramming. PC stem cells (PCSCs) with an increased resistance and distinct metabolic properties are associated with disease relapses and cancer spread, and represent another significant candidate for therapeutic targeting. The present review discusses the metabolic signatures observed in PC, a disease with a multifaceted and often transient metabolic landscape. In addition, the metabolic pathways utilized by PC cells, as well as stromal cells are discussed, providing examples of how they could present novel targets for therapeutic interventions and elaborating on how interactions between the various cell types affect their metabolism. Furthermore, the importance of PCSCs is discussed, focusing specifically on their metabolic adaptations.

Contents

1. Introduction
2. Search tools
3. Distinct metabolic profiles and metabolic flexibility of pancreatic cancer cells
4. Glucose, lactate and the metabolic collaboration in the tumor microenvironment
5. Lipids as essential metabolites and possible clinical markers of PDAC
6. Amino acids are involved in the regulation of pancreatic cancer cell proliferation and dissemination
7. Mitochondrial oxidative metabolism as a therapeutic target
8. Interactions of pancreatic cancer cells with the stromal environment
9. Pancreatic cancer stem cells
10. Conclusions

1. Introduction

Pancreatic cancer (PC) is currently the seventh leading cause of cancer-related mortality, with almost as many deaths as cases; the highest incidence rates are observed in Europe and Northern America (1). With the lowest 5-year survival rate of any cancer type (10%), PC is also projected to become the second leading cause of cancer-related mortality in the United States by the year 2030 (2,3). As pancreatic ductal adenocarcinoma (PDAC) accounts for ~90% of all PC cases (4), the present review focuses primarily on this type of PC.

A genetic susceptibility for PC is related to mutations, such as BRCA2, while other risk factors for the development of this disease include smoking, obesity, diabetes and chronic pancreatitis (5,6). Due to a lack of alarming symptoms at the early stages of the disease, the majority of cases are already an advanced or metastatic stage at the time of diagnosis, and low survival rates are observed even in cases where resection is possible (7,8). Chemotherapy remains the standard treatment option, although gemcitabine monotherapy, as
well as certain combination chemotherapeutic regimens, such as FOLFIRINOX and nab-paclitaxel plus gemcitabine have achieved only minimal survival benefits, while being associated with considerable toxicity issues (9,10). Moreover, advances in the field of cancer immunotherapies have not yet had an impact on PC, mainly due to the dense stromal barrier, which poses an obstacle for the infiltration of immune cells, due to the immunosuppressive environment and the shortage of effector T-cells able to eliminate tumor cells (11). Although attempts to manipulate the immune system in PC have yielded some promising results (12-14), the majority of clinical trials to date have been largely disappointing (15).

Alternative strategies to combat this lethal disease are therefore sought after and the targeting of the deregulated metabolic physiology, which is additionally connected to radio- and chemo-resistance in PDAC, is one of the promising options (16,17). The common genomic alterations, such as the activation of the KRAS oncogene, the deletion of the tumor suppressor gene, SMAD4, or the transformation of the tumor suppressor, p53, into a prooncogenic protein significantly stimulate nutrient acquisition and a variety of metabolic pathways (18). The ability to stratify PDAC tumors into subgroups with distinct metabolic requirements and vulnerabilities could offer valuable prognostic information and may aid in the selection of specific treatments. For example, some studies have identified glycogenic and lipogenic subtypes associated with different survival outcomes and distinct sensitivity to metabolic inhibitors (19,20).

The ability of PC cells to obtain nutrients from their surroundings and through autophagic pathways, unique physiological characteristics of the tumor microenvironment, as well as the interactions of PC cells with non-cancer cells are also among the factors that markedly contribute to the extensively reprogrammed metabolism in PDAC (21). Populations of highly clonogenic, resistant and metastatic PC stem cells (PCSCs) appear to have distinct therapeutic vulnerabilities related to specific metabolic features that could be exploited. Importantly, metabolic plasticity that allows PCSCs to adapt to environmental changes appears to be connected to distinct patterns of DNA methylation and so a disruption of this metabolic-epigenetic crosstalk present within PDA could represent another therapeutic target (22).

The present review discusses a range of metabolic and physiological aspects of PC cells, which play a role in the development and progression of this difficult-to-treat and aggressive malignancy. The present review also focuses on the possibility of targeting PDAC-specific metabolic pathways in order to aid in the development of more effective and personalized therapies. The metabolic pathways discussed herein as taking place in PC cells are summarized in Fig. 1 and the metabolic crosstalk within the tumor microenvironment in PC is illustrated in Fig. 2.

2. Search tools

The PubMed/MEDLINE, Scopus and Web of Science databases were searched with search terms including ‘cell metabolism’, ‘metabolic phenotypes’, ‘metabolic profiles’, ‘pancreatic cancer’, ‘tumor microenvironment’, ‘stem cells’, ‘therapeutic/treatment resistance’ and ‘metabolomics’ in various Boolean combinations as search strings. In order to cover the selected topic comprehensively, articles were searched without a limit on their date of publication. Only published, peer-reviewed articles in the English language were included in the search and literature analysis. The articles were then manually sorted and critically evaluated according to relevance. Based on the database searches, electronic and manual cross-referencing was used to identify additional relevant sources.

3. Distinct metabolic profiles and metabolic flexibility of pancreatic cancer cells

Pancreatic tumors are known to be heterogenic at the cellular level, with distinct metabolic traits and methods of nutrient acquisition, which can lead to issues with effective treatment (23). There is therefore a need for a better understanding of the biological characteristics of PC together with an assessment of metabolic phenotypes of individual tumors in order to lead to the development of more targeted therapeutic strategies. Patient stratification strategies are becoming increasingly useful in cancer diagnosis, prognosis assignment and in creating appropriate treatment strategies. The comparison of mutational profiles has proven problematic with question-able associations between mutational status and disease behavior (24).

Genomic and transcriptomic studies based on molecular profiling have identified subgroups of PDAC often overlapping to varying degrees (25-29). Moffitt et al (26) used PDAC gene expression microarray data to identify and validate two tumor subtypes, ‘basal-like’ and ‘classical’. On a molecular level, the basal-like subtype was similar to basal tumors of the urinary bladder and breast cancer and had a worse outcome. Notably, using the algorithmic separation of tumor, stromal and normal gene expression, they also identified distinct stromal subtypes, which were defined as ‘normal’ and ‘activated’ and were independently prognostic. These findings demonstrate a particular significance of the stromal compartment, which has been shown to play crucial roles in PDAC biology (30-35). It is also becoming clear that further heterogeneity in expression profiles exists within cells of a single tumor (36).

PC cells need to be able to proliferate rapidly, which is complicated by the dense stroma environment, which lacks adequate vasculature and therefore presents a nutrient- and oxygen-poor environment. Cells in such conditions undergo extensive oncoprotein-directed metabolic reprogramming, which includes a higher nutrient acquisition, increased glucose utilization through aerobic glycolysis, an upregulated biosynthesis of lipids and amino acids, alterations in the redox balance, as well as an activation of recycling and scavenging pathways (37-41).

In addition to the molecular signatures of PDAC aforementioned, metabolic subtypes with specific metabolic requirements have also been identified that are of prognostic value and could aid in the selection of treatments and may thus lead to more favorable therapeutic outcomes. Based on broad metabolic profiling, Daemen et al (19) described ‘slow proliferating’, ‘glycolytic’ and ‘lipogenic’ PDAC subtypes, which exhibited different metabolite levels associated with glycolysis, lipogenesis and redox pathways. Studying the
differences between glycolytic and lipogenic lines, they found particularly high levels of phosphoenolpyruvate (PEP) and of the $\text{ENO2}$ mRNA coding for the glycolytic enzyme neuron-specific enolase (ENO2), which converts 2-phosphoglycerate to PEP. The two metabolic subtypes also responded differently to inhibitors of glycolysis and lipid metabolism. Based on these findings, those authors suggested ENO2 inhibitors as a possible therapeutic option for aggressive, fast growing glycolytic tumors where ENO2 was found to be strongly expressed. They also observed a correlation between these subtypes and those identified by Collisson et al. (25), indicating that links indeed exist between molecular and metabolic subtypes. They used their findings to create a model, in which epithelial tumors use glucose for the tricarboxylic acid (TCA) cycle and de novo lipogenesis, whereas mesenchymal tumors preferentially fuel the TCA cycle by glutamine with a potentially enhanced vulnerability to ROS-inducing agents (19).

Yu et al. (42) performed an analysis of the expression of metabolism-related proteins and classified pancreatic tumors derived from patients into categories based on the utilization of glucose and glutamine: Warburg type, reverse Warburg type, mixed type, and null type in glucose-dependent metabolism and canonical type, and non-canonical type, mixed type and null type in glutamine-dependent metabolism. The Warburg type, non-canonical type and mixed types of these two metabolic branches were represented by metabolically active, biologically aggressive and tumors with a poor prognosis. Those authors came to the conclusion that a higher number of metabolic subtypes and categories leads to major differences in survival outcome: The more subtypes and categories PCs employ, the worse the outcome (42). There are other studies focusing on the molecular and metabolic stratification of PDAC tumors (20,43); however, the two important phenotype categories which can be taken out of those are more aggressive, often metastatic glycolytic subtypes commonly featuring the amplified onco-genes, KRAS and Myc, with less favorable clinical outcomes, and lipogenic subtypes with the more prominent utilization of lipid metabolism pathways and a better prognosis. In addition to those studies, an association of particular lipid metabolites
with a worse prognosis in PDAC has recently been highlighted. Performing metabolomic profiling of patient-derived tumor xenografts (PDTX) Kaoutari et al (44) linked increased levels of triacylglycerols with a poor prognosis. They also managed to improve the sensitivity of PDTX-derived primary cells to the cytotoxic drugs gemcitabine, oxaliplatin and 5-fluorouracil by blocking the synthesis of glycerophospholipids (44). It should be kept in mind that interactions involving distinct cell populations within the tumor microenvironment may also contribute to the complex nature of PDAC metabolic phenotypes. Single-cell metabolomics can be used to distinguish different cell types in a heterogeneous cell mixture and to provide information about metabolic specificities of tumor cells from clinical cancer tissues (45). Specifically, a high-throughput, label-free and sensitive dielectric barrier discharge ionization-mass spectrometry (DBDI-MS) platform has been developed for the analysis of single-cell metabolites, which identified deregulated lipid metabolism in PDAC cells and detected a reduction in lipid content after the inhibition of ATP citrate lyase, a rate-limiting enzyme for lipid synthesis, which has high mRNA levels in both patients with PDAC from The Cancer Genome Atlas dataset, as well as PC cell lines (45). Distinguishing metabolic variations among the subsets of cell populations on a single-cell level is also possible via a complex metabolic profiling method single cell energetic metabolism by profiling translation inhibition (SCENITH) or by measuring multiple enzymatic activities reflecting different metabolic pathways at saturating substrate conditions at single cell resolution (46,47). SCENITH is based around puromycin labeling and flow cytometry measurements of protein synthesis, reflective of global cellular metabolic activity. It can be used directly in heterogeneous human tumor samples to study metabolic profiles of multiple cell types. The analysis of single cell enzymatic activities within a native tissue microenvironment relies on enzyme histochemistry and automated histocytometry to identify particular cell types and simultaneously characterize intra- and intercellular metabolic configurations (46,47).
Metabolic phenotypes of cancer cells can be transient. For example, progressively de-differentiated PC cells have been shown to undergo a shift from glycolytic to oxidative metabolism, resulting in a quiescent state. Following the re-differentiation, these cells regained their proliferative capacity and glycolytic metabolism, commonly associated with a greater aggressiveness (48). Metabolic switches in PDAC cells can occur also as a response to disruptions caused by treatments (39,49). It is thus of utmost significance to understand the underlying mechanisms, as it could help either to prevent, overcome or even exploit such metabolic plasticity.

4. Glucose, lactate and the metabolic collaboration in the tumor microenvironment

The enhanced utilization of glucose by tumor cells even under normal oxygen levels was observed by Otto Warburg as early as the 1920s and was later defined as the Warburg effect (50). Since then, the importance of the Warburg phenotype in cancer cells has been well-documented. Its advantages lie in the quick supply of ATP, the support of increased biosynthetic needs, the modification of chromatin structure and redox regulation (51,52). Moreover, the produced and exported lactate contributes to immunosuppression within the tumor microenvironment (53). To compensate for the relatively low ATP output compared to mitochondrial oxidative phosphorylation (OXPHOS), the uptake of glucose can be increased by an overexpression of the glucose transporter 1 (GLUT1) (54). Additionally, phosphorylation on Ser226 in GLUT1 was identified as a key event for the enhanced cell surface localization and overexpression of GLUT1 (GLUT1) (54).

The enhanced glucose uptake by tumor cells is facilitated by hypoxia, promotes glucose uptake and the production of lactate via glycolysis. MCT-1 expression on the other hand is dependent on oxygen and is repressed by hypoxia (67). It facilitates lactate uptake by cells, which is then used as a substrate in the TCA cycle for ATP production in OXPHOS (68). Cells expressing MCT-1 have a well-developed mitochondrial network and produce large amounts of TCA intermediates and ATP (41). This led to the development of a model of PDAC where aerobic cells in normoxic regions utilize OXPHOS fed by lactate produced by hypoxic cells and imported through MCT-1, leaving glucose to be preferentially used in aerobic glycolysis by cells growing at low oxygen pressure (65). A similar collaboration appears to exist between cancer cells and stromal resident cells. Cancer cells induce oxidative stress and aerobic glycolysis in cancer-associated fibroblasts (CAFs) and subsequently use energy-rich metabolites lactate and pyruvate secreted by CAFs to sustain their own increased proliferation (69,70). The G1-coupled receptor GPR81 was confirmed to be expressed in several cancer cell lines, including those of PDAC and to play a critical role in sensing extracellular lactate (71). Its activation leads to an increased expression of MCTs, CD147 and peroxisome proliferator-activated receptor-γ co-activator PGC-1α which, apart from its ability to increase MCT1 expression, engages in a spectrum of biological processes (72). PGC-1α is strongly linked to the regulation of glucose and fatty acid metabolism, fiber type switching in skeletal muscle, adaptive thermogenesis and heart development as well as the stimulation of mitochondrial biogenesis (73). The silencing of GPR81 has been found to negatively affect the mitochondrial activity of cancer cells grown in cell culture conditions, with only lactate as an available energy source. Roland et al (71) also observed that the loss of GPR81 was associated with a reduced PC tumor growth and metastasis in vivo. Following these findings regarding the key role of lactate metabolism in cancer progression, researchers have begun to explore potential benefits of the inhibition of MCTs and CD147 in PDAC and beyond (74-78).

Finally, Lau et al (79) demonstrated the importance of studying tumor cellular metabolism within heterogeneous systems, which contain different cell types to identify dependencies that may not be evident from studying isolated cells in culture. They used isotope-labeled nutrient tracing in macro-molecules to detect increased pyruvate carboxylation of PC cells relative to fibroblasts in murine PC organoid-fibroblast co-cultures and tumors and then demonstrated that a loss of enzymes with pyruvate carboxylation activity (malic enzyme 1 and pyruvate carboxylase) had a minimal effect on PC cell proliferation in monoculture, whereas it reduced the growth of organoid co-cultures compared to the controls (79).

5. Lipids as essential metabolites and possible clinical markers of PDAC

Lipids support cancer progression via multiple mechanisms, including the formation of biomembranes, participation in cellular signaling and as an energy source (80). Depending on the microenvironmental conditions, as well as currently active metabolic pathways, PC cells can direct glucose or glutamine-derived carbons to increase the synthesis of fatty acids (19). Notably, increased levels of fatty acid synthase (FASN) involved in de novo lipid synthesis have been shown to be associated with a worse prognosis of patients with PC (81). As for the possible underlying reasons behind this association, FASN was previously associated with the HER2-P13K/AKT signaling axis and shown to exert a prominent effect on the proliferation and migration of cancer cells (82). Additionally,
acidic extracellular conditions could lie behind the transcriptional upregulation of FASN by means of epigenetic modifications (83). It is not unreasonable to suggest that similar processes could be taking place in PC, where the increased expression of other lipogenic genes has been found (19). Furthermore, FASN knockdown has been found to lead to an increased responsiveness of PC cells to gemcitabine, as well as radiation treatments, thus creating a link between the overexpression of FASN and treatment-resistant phenotypes (16). In a more recent study, a paclitaxel-poly(lactic-co-glycolic acid) nanoparticle formulation was able to inhibit de novo lipid synthesis, alter membrane stability and improve anticancer efficacy of gemcitabine in PC cells, further emphasizing the importance of lipid metabolic signaling in PC chemoresistance (84). Aside from FASN, stearoyl-CoA desaturasel (SCD1) is another central lipogenic enzyme that contributes to the progression of cancer. SCD1 is important for keeping the correct composition of cancer cell membranes, where monounsaturated phospholipids provide protection from oxidative stress (85,86). Taken together with the fact that the inhibition of SCD1 appears to cause obstructions in aberrant RAS and AKT signaling often involved in the development and progression of PDAC, it could represent a potential therapeutic target (87,88).

An increased amount of free, newly synthesized fatty acids, such as palmitate could be toxic for cancer cells with apoptosis as the likely outcome. Therefore, a controlled release of fatty acids from intracellular lipid stores, where they are stored in the form of triglycerides, by intracellular lipolysis is crucial for preventing that scenario (89). Apart from de novo synthesis, PC cells can obtain fatty acids also from the circulation from food digestion or from fatty acid release from the adipose tissue. This may present an obstacle, as it could render the aforementioned inhibition of the endogenous fatty acid synthesis in PDAC insufficient with regard to antitumor effects, making it hard to justify as an isolated therapeutic approach. The ability of cancer cells to use fatty acid uptake in addition to de novo fatty acid synthesis could help to explain why obesity with characteristically elevated fatty acid plasma levels and a high-fat diet are among the potential risk factors for cancer development and worse clinical outcomes of malignances (38,90-94).

Cholesterol and its synthetic pathway have numerous functions in cancer cells, supporting their growth, proliferation and migration (95). Both the targeting of exogenous cholesterol uptake in PC cells through the shRNA silencing of low-density lipoprotein (LDL) receptor (96) and the inhibition of 3-hydroxy-methylglutaryl-CoA reductase (HMG-CoA reductase), a key enzyme in cholesterol synthesis, by statins has exhibited promising anticancer effects (97). An inhibition of HMG-CoA reductase can also disrupt the process of protein prenylation, an essential process for the activation of signaling proteins including KRAS, which could be exploited to further target cancer cells (98). It is, however, uncertain whether statins may be used as a monotherapy for cancer, as their therapeutic efficacy in clinical trials is controversial (99). For example, pravastatin, a potent HMG-CoA reductase inhibitor, has been found to significantly prolong the survival of patients with advanced hepatocellular carcinoma (HCC) in one study (100), while in another clinical study, the same statin did not improve the survival of patients with advanced HCC, despite the high doses (40-80 mg/day) administered (101). Nevertheless, their use, specifically in combination with other agents, such as FASN inhibitors, remains of pharmacological interest.

Looking at the metabolic rewiring in PDAC and specifically, at the alterations of lipid metabolism in the context of genomie alterations, inactivating mutations of the TP53 gene that often precede the emergence of metastatic tumors stand out in particular. Recently, mass-spectrometry-based lipidome profiling in combination with the transcriptomics of in vitro models and patients with PDAC revealed that the loss of p53 caused a deregulation of intracellular and secreted lysophospholipids with the suggestion that this class of lipids may play a role in p53-mediated non-cell-autonomous molecular signaling, which causes the remodeling of the cancer microenvironment and contributes to immune evasion during PDAC pathogenesis (102).

In addition to rendering the treatment of PDAC more effective, it is crucial to spot its onset early. Biomarkers with optimal specificity and sensitivity for an early diagnosis of PC are therefore much sought after. Within that context, altered serum levels of several lipid metabolites, such as very-low-density lipoprotein, LDL, high-density lipoprotein, 3-hydroxybutyrate, lysophosphatidylcholine, phosphatidylethanolamine and bile acids, such as taurocholic acid were identified (103,104). Recently, Wang et al (105) combined machine learning and metabolomics to select lipids, such as diacylglycerol and lysophosphatidylethanolamine for their detection in PDAC patients' serum and proposed the potential clinical application of their liquid chromatography-mass spectrometry-based targeted lipidomics assay for the effective and accurate auxiliary diagnosis of PDAC. Analyzing the lipid content in pancreatic tissue could also be used to distinguish chronic pancreatitis from PC, e.g., through the employment of NMR spectroscopy (106).

6. Amino acids are involved in the regulation of pancreatic cancer cell proliferation and dissemination

As a consequence of the use of aerobic glycolysis for ATP production and the conversion of pyruvate to lactate, cancer cells use other mechanisms to secure the fueling of the citric acid cycle than the conversion of pyruvate of glycolytic origin to acetyl-CoA and then to citrate. An increased dependence on glutaminolysis, which is accompanied by nicotinamide adenine dinucleotide phosphate (NADPH) production and changes in the activity of corresponding enzymes is one particular mechanism through which cancer cells maintain the proper function of the Krebs cycle (107). This allows such cells to reserve glucose-derived carbon for the use in biosynthetic pathways, such as the pentose phosphate pathway, which ultimately yields NADPH and substrates for the synthesis of ribonucleotides (108,109). NADPH, as a glutathione reductase (GR) co-substrate, plays a role in maintaining the reduced pool of glutathione important for reactive oxygen species (ROS) scavenging (110). Stepping aside from the important role of glutamine metabolism in maintaining the appropriate levels of ROS in cancer cells, the metabolism of other amino acids has also been identified as a possible target for the disruption of the redox homeostasis in PC cells. The inhibition of the
import of oxidized cysteine has been shown to cause a redox imbalance and subsequent ferroptosis in targeted cells (111). This points at a critical dependency of PDAC cells on cysteine contribution to the synthesis of glutathione and coenzyme A to endure elevated lipid ROS production, typically elicited by oncogenic signaling to stimulate tumor growth (111).

The mitochondrial production of citrate from glutamine in a multistep process and its subsequent conversion to cytosolic acetyl-CoA links glutaminolysis with fatty acid synthesis to support the growth of cancer cells in vivo (112). Glutamine also serves as a substrate in the hexosamine phosphate synthesis and is critical for the replenishment of nucleotides, as well as amino acids pools (113-115). Bott et al (116) found that in glutamine-deprived PDAC cells, the glutamate ammonia ligase-mediated de novo synthesis of glutamine was critical for the transfer of the terminal amide nitrogen to nucleotides and hexosamines and subsequently, for their growth. Among the enzymes present in cancer cells that are responsible for the production of glutamine-derived α-ketoglutarate are glutamate-dehydrogenase (GDH), alanine aminotransferase (ALT or GTP), phosphoserine aminotransferase 1 and aspartate transaminase (AST or GOT) (117). In PC, a so-called non-canonical glutamine metabolism pathway is prominently used, where glutamine is first converted to aspartate, which is then converted to oxaloacetate by GOT1 in the cytoplasm. This NADPH-producing pathway concludes with the formation of malate and later pyruvate. An oncogenic form of the KRAS protein has been shown to be associated with the establishment of this non-canonical pathway of glutamine metabolism in a study on PDAC (118). This growth advantage-conferring pathway can also be stimulated by hypoxia, often observed in PDAC cells: The PI3K/mammalian target of rapamycin complex (mTORC) 2 pathway targets hypoxia-inducible factor 2-α (HIF2-α) with a consequent transcriptional activation of GOT1 (119). Recently, it has also been confirmed in PDAC cells that the uncoupling protein 2 (UCP2)-mediated transport of glutamine-derived aspartate from mitochondria to cytosol is critical for the generation of NADPH in this pathway. Notably, UCP2 silencing has been shown to markedly suppress the growth of KRASmut PDAC cells (120).

Multiple research teams have tried to confirm the critical importance of this non-canonical pathway of glutamine metabolism in PC. In a previous study, a pan-inhibitor of transaminases, aminooxyacetate (AOA) negatively affected the growth of PDAC cell lines; however, non-transformed human pancreatic ductal cells and human diploid fibroblasts remained largely unaffected (118). The authors of that study suggested, however, that the sensitivity of cells to AOA was dependent on whether or not oncogenic KRAS was present to support the anabolic metabolism of glutamine. Encouragingly, the decreased ability of PDAC cells to combat oxidative stress after an impairment of Gln metabolism could significantly increase the success rate of the whole approach (118). In another study, the inhibition of mitochondrial GOT2 led to a marked induction of cyclin-dependent kinase inhibitor p27-mediated cellular senescence and the growth suppression of PDAC cells. This effect was not observed in non-transformed cells (121).

Apart from oncogenic KRAS signaling, other regulatory mechanisms exist in PDAC that modulate the metabolism of amino acids and provide for the metabolic needs of cancer cells. The MYC oncogene positively regulates glutamine uptake and causes a suppression of microRNAs (miRNAs/miRs) with an inhibitory effect towards glutaminase (GLS) (122,123). Son et al (118) demonstrated that a chemical inhibition of GLS had a growth-suppressive effect on both human and mouse PDAC cells. However, Roux et al (124) observed a decreased activity and mRNA levels of GLS in the majority of the analyzed PDAC cells. Those cells had an increased activity, mRNA and protein expression of glyceral-3-phosphate acyltransferase and carbamoyl phosphate synthetase II, which allowed them to produce nucleotides and glutamate, as well as upregulated levels of alanine serine cysteine transporter 2 responsible for glutamine import. GDH and AST/GOT were other enzymes with an elevated activity. Another study demonstrated that the activity of Myc itself could be regulated by RNA and that expression levels of long non-coding RNA (lncRNA) XLOC_006390 were specifically associated with changes in glutamate metabolism, proliferation and migration of PC cells (125). It was found that this specific lncRNA functioned by binding to c-Myc and preventing ubiquitination with the final result being the increased stability of the transcription factor that binds to the promoter of GDH1 and acts as its transcriptional activator. Of note, He et al (125) suggested that it was the XLOC_006390/c-Myc signaling axis resulting in the upregulation of GDH1 expression that was associated with worse survival times of patients with PC rather than the expression of other enzymes involved in the α-ketoglutarate supply.

In conditions with a low glutamine availability, the transcription factor p53 is a chief participant in pro-survival signaling and can help cancer cells to overcome such a nutritional challenge by stimulating the expression of transporters, facilitating the import of other amino acids. Aspartate and arginine can be taken up by cells more robustly due to the involvement of p53, with the latter amino acid capable of activating the mTORC1, and in turn promoting tumor growth (126,127). In addition to wild-type p53, mutated p53 can also play a role upon a glutamine withdrawal to promote tumor cell survival via an induction of p21 resulting in cell cycle arrest (128). Taken together, p53 can act in conjunction with mTORC1 either towards stopping or promoting cell proliferation in a context-dependent manner, with factors such as the type of stress stimulus and the mutational status of p53 likely to be involved.

Other tumor suppressors frequently mutated in cancer cells have been linked to the altered cellular metabolism of various types of cancer, including PDAC (18). A homozygous deletion of the tumor suppressor gene locus SMAD4, which occurs in PDAC and can cause the loss of the malic enzyme 2 (ME2), was previously exploited to disrupt NADPH production, mitochondrial redox homeostasis and amino acid metabolism. The simultaneous deletion of both mitochondrial malic acid enzymes ME2 and ME3 led to a suppressed transcription of branched-chain aminotransferase ½ and thus impeded the transfer of amino groups from branched chain amino acids to α-ketoglutarate. As a consequence, glutamate could not be resynthesized efficiently and the de novo nucleotide synthesis was also impaired (129). This approach could be potentially therapeutically beneficial in patients with PDAC with a homozygous deletion of the SMAD4 locus, who constitute approximately one-third of PDAC cases and who, at the same time, have ME2 deletions (129).
Aberrant metabolism can lead to epigenetic alterations associated with an uncontrolled proliferation, as the activity of chromatin-modulating enzymes involved in the regulation of DNA transcription is dependent on the presence of cellular metabolites, such as acetyl-coenzyme A and S-adenosylmethionine (130-132). Kottakis et al (133) established how a concrete metabolic state interconnected with epigenetic processes contributes to the oncogenic transformation in pancreatic cells with concurrent LKB1 and KRAS mutations. An interrelation was found between the generation of excess S-adenosylmethionine induced by the mTOR-dependent channeling of glucose and glutamine-derived intermediates into the serine-glycine-one carbon pathway, and transcriptional silencing through DNA methylation (133).

The importance of amino acids is also apparent when it comes to the transcriptional regulation of the Snail family of EMT transcription factors (EMT-TFs). These EMT-TFs suppress E-cadherin, and other epithelial markers and adhesion molecules, and increase the expression of matrix metalloproteinase (MMPs), thus stimulating EMT, which often precedes the metastatic spread of cancer cells (134). Arginine additionally supports PDAC cell dissemination by serving as the precursor for the synthesis of nitric oxide (NO), while glutamate has been shown to stimulate the metastatic spread in PC, functioning through its neurotransmitter receptors (135,136). Specifically, the depletion of arginine has been found to impede the migration, adhesion and invasion of PC cells with a lower expression of EMT-TFs, extracellular matrix-rebuilding MMPs and an increased expression of the epithelial marker, E-cadherin (134). The use of arginine deprivation in the treatment of PC could also achieve more prominent antitumor effects. It may thus combat the development of therapeutic resistance with a simultaneous use of cytotoxic agents, such as gemcitabine or when combined with the inhibition of other metabolic pathways in PDAC cells, including those belonging to glutamine metabolism, serine biosynthesis or polyamine biosynthesis (137,138).

Finally, to be able to cope with a situation when nutritional deficiencies arise, PDAC cells are well-adapted to take advantage of extracellular nutrient sources available in the microenvironment. When needed, they can utilize protein-macropinocytosis to obtain important amino acids by lysosomal degradation, as well as autophagy to recycle proteins, macromolecules and whole organelles and to refill essential nucleotide pools (139-143). Additionally, autophagy in PC supports immune evasion and is required for proper cystine transport and cysteine homeostasis by promoting the localization of the cystine transporter SLC7A11 at the plasma membrane (144,145). Notably, Maertin et al (140) found that while the basal autophagic activity of PC cells was relatively high, amino acid depletion and hypoxia activated autophagy only weakly, if at all. As regards the precise regulation of the autophagic process, they confirmed the stimulation of basal autophagy by the oncogenic activation mutation in KRAS GTPase and by the consequently stimulated OXPHOS. A limitation of amino acid supply to suppress OXPHOS was also mentioned as a potential option for the treatment of PDAC (140).

7. Mitochondrial oxidative metabolism as a therapeutic target

It is no longer controversial that numerous cancer cells have fully functional mitochondria performing OXPHOS, depending on the oxygen availability in the particular tumor site, the amount of available metabolites capable of fueling the TCA cycle and the required regulation state. This is contrary to the previous hypothesis of universally diminished OXPHOS activity with defective mitochondria whenever glycolysis was found to be upregulated in tumors (146).

Substrates produced by fatty acid oxidation, glycolysis and glutaminolysis enter the TCA cycle, which extracts electrons passed on to NADH and flavoproteins. A constant supply of electrons is necessary for the creation of a transmembrane proton gradient and the efficient production of ATP by the electron transport chain complexes and ATP synthase in the inner mitochondrial membrane (147). The transport of these electrons can lead to the generation of ROS in mitochondrial complexes of the electron transport chain (148). Oncogene-inducible ROS can support anchorage-independent cancer cell growth by decreasing the phosphorylation of ERK1/2 in the ERK MAPK signaling pathway to levels that are compatible with cellular proliferation and as such, were described as a factor supporting KRAS-driven tumorigenicity (149). Attempts to target the TCA cycle in PDAC to suppress mitochondrial metabolism are currently ongoing, with a protocol that includes the lipoyc acid analogue, devimistat, which selectively inhibits the TCA cycle by impairing the activity of pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, combined with the modified FOLFIRINOX regimen (150).

Within a cohort of patients with PDAC, tumors with heterogeneous OXPHOS rates have been discovered and the high OXPHOS activity with high amounts of complex I mRNAs and proteins could be used as a helpful biomarker to identify tumors vulnerable to substances, such as phenformin in combination with traditional chemotherapy (151). The cause for optimism with this type of treatments is the fact that they could be applied independently of the main genetic alterations forming the causal background of the majority of PDAC cases, such as KRAS mutations, and that the antitumor effects of phenformin with gemcitabine were successfully replicated in vivo (151). It was hypothesized that after inhibiting OXPHOS at complex I with phenformin, the affected cells would lose the protection from the stress caused by the inhibition of DNA synthesis by gemcitabine (151). The clinical confirmation of those results remains to be performed, at least to the best of our knowledge.

To improve the results of OXPHOS inhibition, combined treatments using several compounds will likely be required. For example, Candido et al (152) based their experiments on the findings of metformin-mediated autophagy induction through the suppression of mTORC1 activity. Using metformin, they increased the anti-proliferative effects of the mTOR inhibitor, rapamycin, in PDAC cell lines (152).

Attention should be paid to the possibility of potential disease relapses when cancer treatments targeting mitochondrial metabolism are used. An adaptation to OXPHOS inhibition by a fraction of tumor cells that can switch to glycolysis and vice versa was previously described in PCSCs, where their metabolic phenotype observed at a particular time depended
on MYC/PGC-1α balance (39). These highly metastatic and treatment-resistant cells capable of tumor repopulation were previously described as more reliant on the OXPHOS pathway and thus could represent an interesting cell subpopulation in PC to be targeted by OXPHOS inhibiting drugs (17). The inhibition of OXPHOS could further benefit cancer patients by lowering tumor hypoxia, which can interfere with the efficacy of treatments. An oxygen consumption decrease in better accessible normoxic regions could lead to a higher oxygen tension across the microenvironment of the whole tumor, leading to an improvement of the anticancer effects in initially hypoxic regions (146). Finally, carefully selected medications aimed at increasing tumor oxygenation could help in the quest to identify strategies with which to suppress treatment resistance in a number of cancer cases, as exemplified by an improved response to radiotherapy following the administration of metformin in a prostate cancer in a study using xenografts (153).

8. Interactions of pancreatic cancer cells with the stromal environment

The extracellular environment in PC consists of a desmoplastic tissue composed of collagen fibers, dissolved growth factors, metabolites and diverse stromal cells, among which CAFs, stellate cells and activated macrophages are strongly represented (154). Drug penetration through this dense, fibrotic tissue barrier can be problematic, which together with frequently occurring hypovascularity, adds to the intrinsic chemoresistance of PDAC (154). This desmoplastic environment can be advantageous for cancer cells, while at the same time forming an obstacle to their access to growth factors and metabolites and for the metastatic spread. A proteolytic breakdown of stromal tissue facilitated by plasminogen activation system, as well as MMPs expressed by CAFs and tumor cells can help tumor growth and invasion (155). SerpinB2 was previously identified as a regulator of stromal remodeling of collagen in PDAC, with its enzymatic target urokinase plasminogen activator (uPA) emerging as a novel PDAC prognostic marker (156). The non-universally beneficial implications of the fibrotic stroma on PDAC cells have been reflected in reported findings regarding the role of tumor microenvironment in PDAC (157-163). Olive et al (160) discovered that the depleting of tumor-associated stromal tissue by the inhibition of the Hedgehog cellular signaling pathway enhanced the delivery of chemotherapy in a mouse model of PC, which led to a transient stabilization of the disease. By contrast, Croucher et al (155) pointed out the association between reduced stromal integrity and tumor growth, as well as local invasion in PC.

Pancreatic stellate cells (PSCs) are primarily responsible for the maintenance of normal stromal tissue architecture; however, in the case of a repeated or sustained pancreatic injury, as well as during PC, they become perpetually activated. Apart from causing pathological fibrosis, important supporting roles of activated PSCs towards adjacent cancer cells have been uncovered (164). Signals derived from stromal cells in the form of secreted factors regulate the expression of various genes in PC cells, including those connected with the cell cycle, DNA replication and metabolic pathways. Those signals can increase glycolytic metabolites, the pentose phosphate pathway, nucleic acid synthesis and the TCA cycle, which translates into the increased viability of PDAC cells under nutrient-deprived conditions (33). Of note, genes activated by stromal cues have been found to overlap with genes activated by the KrasG12D allele, suggesting a cooperation of stromal components and oncogenes in transcriptionally driven PC progression (33). Furthermore, oncogenic KRAS switches on Sonic hedgehog secretion by PDAC cells to activate PSCs and triggers heterocellular crosstalk, which leads, together with multiple phosphorylation events via an IGFR1/AXL-AKT axis, to an increased mitochondrial capacity in tumor cells (35).

In an effort to elucidate the mechanisms through which the stromal secretome can alter gene expression in PDAC cells and to identify potential novel therapeutic targets, Sherman et al (33) uncovered the histone acetylation at promoter and enhancer regions of functionally relevant genes as a key mediating event. In their concluding remarks, they also proposed the hepatocyte growth factor, insulin-like growth factor binding proteins 2, 3, 7 and MYC-activating, PSCs-produced II-6 as possible microenvironment-derived factors inducing transcriptional and metabolic changes in the epithelial compartment.

The cooperation between stromal and cancer cells can take on a different form as PDAC cells can manipulate PSCs to actively use autophagy and secrete non-essential amino acids (NEAs). Those alternative carbon sources are then captured by PDAC cells and serve to support TCA anaerobiosis, lipid and NEAA biosynthesis when other drivers of these pathways such as glucose or glutamine become scarce (34). It has been determined that oxidative stress induced by cancer cells in the adjacent stromal cells may be behind the autophagy activation in PSCs with the resultant stromal overproduction of recycled nutrients benefiting cancer cells by driving mitochondrial biogenesis and anabolic growth (165). Additionally, the excess stromal ROS production enhances the antioxidant defense in nearby cancer cells and contributes to their genomic instability (165). It has also been suggested that autophagy in CAFs could be induced by ammonia produced by cancer cells during glutaminolysis and diffused into the microenvironment, which could lead to a positive feedback, with subsequent high levels of glutamine secreted into the TME by CAFs increasing the conversion of glutamine to glutamate and ammonia along with mitochondrial activity in cancer cells (166,167). A supportive role of the metabolic scavenging in PDAC is further evidenced by the confirmed existence of CAF-derived exosomes containing mRNA, miRNA, intact metabolites and TCA cycle intermediates, which promote PC cell proliferation, migration and chemoresistance in a mechanism similar to macropinocytosis under nutrient-depleted conditions (31,168-170). Aside from acting as a direct source of metabolites, such exosomes could create a hypoxia-mimicking microenvironment stimulating the reductive carboxylation of glutamine in cancer cells, the pathway previously observed in rapidly growing malignant cells and identified to be an alternative to oxidative metabolism as the major source of citrate and precursors for macromolecular synthesis (168,171).

Under conditions of nutrient stress, PDAC cells can also take up collagen fragments from the surrounding stroma either through macropinocytosis-dependent or independent mechanisms. Following the breakdown of extracellular matrix
proteins, collagen-derived proline is further metabolized to support the TCA cycle and to promote PDAC cell survival and proliferation (172). Moreover, following their activation by PDAC cells, fibroblasts start to produce higher amounts of type I collagen, which enhances integrin-FAK signaling in PDAC cells, resulting in an increased PDAC clonogenic growth, self-renewal and the frequency of cancer stem cells (CSCs) (173).

In addition to stromal fibroblasts, PC cells can interact with different cell types within the tumor microenvironment. Adipocytes can acquire a mesenchymal phenotype characterized by decreased lipid content and energy utilization after a de-differentiation caused by a co-culture with PC cells. Adipocytes with this phenotype can increase PC cell aggressiveness in vitro and can also contribute to matrix remodeling (174). Meyer et al (175) established a model of adipocyte-induced proliferation of PC cells enhanced by nutrient-poor conditions, demonstrating that adipocytes secreted glutamine and initiated its transfer to cancer cells after their own catabolism of the same metabolite was downregulated by PC cells (175).

Other intercellular interplay found to contribute to the malignant progression of PDAC involves tumor-associated macrophages (TAMs). By secreting the cytokine, CCL18, M2 TAMs can activate the NF-κB signal transduction pathway in PDAC cells and thus induce their expression of the adhesion molecule, vascular cell adhesion molecule-1, which subsequently enhances aerobic glycolysis in PDAC cells. Lactate produced by PC cells reciprocally facilitates the M2-like polarization of macrophages, thus creating a positive feedback loop (176). Due to the ability of lactate to modify the host antitumor immune response, its increased production contributes to the formation of an immunosuppressive tumor niche and the improved survival of metastatic cells, as shown by the improvement of the natural killer cell cytolytic function towards LDHA-deficient PanO2 cells in mice (53).

Intercellular interactions in the pancreatic tumor stroma may also include short-range interactions through gap junctions or the transfer of mitochondria between PC cells and other stromal cells, including mesenchymal stem cells (MSCs), as has been shown for other types of cancer (177). CAFs have been shown to influence the metabolism and support the malignant progression of non-small cell lung cancer (NSCLC) cells through connexin-43 gap junctions (178). Of note, the outward transfer of mitochondria mediated by cell adhesion and tunneling nanotubes from Jurkat cells, which had an increased level of ROS after a cytotoxic treatment, to MSCs was shown to cause chemoresistance in Jurkat cells (179). Multiple myeloma cells can also receive mitochondria from their microenvironment, which can lead to changes in their metabolism, resulting in a more prominent use of OXPHOS (180). It is possible that similar intercellular interactions may be present in pancreatic tumors. In fact, the role of connexin-43 channels in exporting lactate from glycolytic PDAC cells to sustain their metabolism and growth when an outward MCT transport is inhibited by extracellular acidity, as well as to provide substrate for OXPHOS of cells in better-perfused areas, where there is also a more favorable transmembrane gradient for MCT-facilitated lactate off-loading(181). It would thus be of interest to examine whether other such mechanisms play a role in PC tumors.

9. Pancreatic cancer stem cells

CSCs are a highly-chemoresistant subpopulation of cells within tumors capable to self-renew and replenish the cancer cell population following chemotherapy, which leads to the recurrence of the disease. The importance of eradicating these cells to successfully treat cancer has become clear (182-184). A tremendous effort has been placed in identifying potential biomarkers for PCSCs over the years, so they could be isolated and targeted. For this purpose, multiple surface markers expressed by these undifferentiated cells were identified, such as CD44, CD24, EpCAM, CD133, CXCR4, ALDH1 and hepatocyte growth factor receptor c-MET (185-189). To further expand the options of the detection and isolation of CSCs in different types of cancer, Miranda-Lorenzo et al (190) used autofluorescence as an exclusive marker of CSCs from solid human tumors, including that of PDAC. Such cells expressed pluripotency-associated genes and displayed chemoresistance, long-term tumorigenicity and invasiveness in vivo, traits suggestive of their stem-like identity. As to what potential advantage could these cells gain from having this autofluorescent phenotype, e.g., during hostile conditions after chemotherapy, it was hypothesized that riboflavin stored in the CSC autofluorescent vesicles could be used for the synthesis of flavin-dependent coenzymes and flavin nucleotides, factors important for the setting up of an antioxidant defense system (191,192). Additionally, certain genes that are differentially expressed and distinguish stem cells in the normal pancreas could be potentially used to identify stem-like cells in various tumors (193).

Advances in the identification and isolation of PCSCs uncovered their association with PSCs and CAFs. These stromal cells create a paracrine niche for PCSCs by secreting factors, including Nodal/Activin, hCAP-18/LL-37 and ISG15, and enhance their stem cell-like phenotypes along with their tumorigenic potential (30,194,195).

In keeping with the exceptional ability of PCSCs to survive stressful conditions, one would predict the occurrence of specific metabolic adaptations in these cells. Indeed, an increased utilization of OXPHOS by PCSCs could confer to them some resistance in situations when glucose or glutamine is limited, as well as during other situations affecting their specifically adjusted metabolism, such as the ablation of K-Ras oncogene (17,39). Importantly, oxygen deprivation typical for the tumor microenvironment of PDAC does not prevent the ability of PCSCs to use OXPHOS; instead, hypoxia supports autophagy and favors their survival and migration (196,197). A higher reliance on OXPHOS could, however, be an issue for PCSCs as the ROS produced by this pathway need to be detoxified to maintain their stemness. Jagust et al (198) demonstrated their dependency on glutathione metabolism, which was confirmed by the significantly diminished CSC self-renewal and chemoresistance after a pharmacological targeting of this antioxidant pathway. Similar to their non-CSCs counterparts, PCSCs can utilize multiple seemingly crucial metabolic pathways. The targeting of the non-canonical glutamine metabolism pathway in PCSCs was shown to negatively affect their self-renewal, elevate their intracellular levels of ROS and
subsequently increase their radiosensitivity (199). Apart from glutamine, the inhibition of fatty acid synthesis and mevalonate pathways caused an anti-proliferative effect in PCSCs that was greater than that in parental PC cells, suggesting that their utilization of metabolic substrates could be heterogeneous, often dependent on the microenvironmental context (200).

Epigenetic alterations connected with distinct metabolic pathways in PCSCs probably predetermine their metabolic plasticity, which allows them to respond promptly to different environmental challenges and enhances their tumorigenicity. Notably, chromatin modifications linked to distant metastatic subclones was reversed by targeting a specific metabolic enzyme in a PDAC study, with those results further supporting metabolism-epigenome links in cancer (201). Currently, knowledge is expanding regarding the factors behind the metabolic plasticity of PCSCs, which needs to be overcome if this highly resistant cellular subpopulation is to be eliminated in PDAC tumors. The impairment of mitochondrial ISGylation critical for the recycling of dysfunctional mitochondria disrupts PaCSC mitochondrial metabolism, consequently affecting their metabolic plasticity and rendering them susceptible to a prolonged inhibition with metformin in vivo (202). Recently, it was also demonstrated that the unique metabolic signatures of PCSCs mediate organ-specific metastasis, which further points to the importance of metabolic programming of this cellular entity (203).

10. Conclusions and future perspectives

Therapeutic options for PDAC are still limited mainly to surgery and cytotoxic chemotherapy. The targeting of the reprogrammed cancer metabolism provides an innovative therapeutic strategy to be used also in combination with cytotoxic agents to achieve greater effects. Such applications already exist. Devinitast, a drug that inhibits key enzymes for the functioning of the TCA cycle in tumor cells in combination with the modified FOLFIRINOX, protocol led to a response rate of 61% in patients with metastatic PC in an open-label, phase I trial (NCT01835041) (204) and a phase-III clinical trial to evaluate efficacy and safety of the same combination of drugs in patients with metastatic adenocarcinoma of the pancreas is ongoing (205). The cell autophagy inhibitor, hydroxychloroquine, in combination with cytotoxic agents or ERK/MAPK pathway inhibitors is currently being tested for effectiveness in PC clinical trials (NCT01506973; NCT04145297; NCT03825289 and NCT04132505).

It is likely that further such therapeutic strategies can be developed based on a detailed understanding of the metabolic flexibility and needs of cancer cells together with the metabolic cooperation and signaling within the tumor microenvironment.

Acknowledgements
Not applicable.

Funding
No external funding was received.

Availability of data and materials
Not applicable.

Authors’ contributions

Both authors (MZ and JT) conceived the present review article. MZ collected the literature and drafted the manuscript. JT made critical revisions to the manuscript. Both authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
Both authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.
2. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Marias LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913-2921, 2014.
4. Sarantis P, Koutras E, Papadimitropoulou A, Papavassiliou AG and Karamouzis MV: Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 12: 4298-4321, 2021.
5. Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY and Gao F: Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 27: 4298-4321, 2021.
6. McGuigan A, Kelly P, Turckington RC, Jones C, Coleman HG and McCain RS: Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24: 4829-4861, 2018.
7. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
8. Piccozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS and Kozarek RA: Five-year actual overall survival in resected pancreatic cancer: A contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol 24: 1722-1730, 2017.
9. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013.
10. Conroy T, Hammel P, Hebbah M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, et al: FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379: 2395-2406, 2018.
11. Upadhrasta S and Zheng L: Strategies in developing immunotherapy for pancreatic cancer: Recognizing and correcting multiple immune ‘defects’ in the tumor microenvironment. J Clin Med 8: 1472, 2019.
12. Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Souten MC, McGarvey M, Nelson AM, et al: Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155: 32-93, 2018.
13. O’Hara M, O'Reilly E, Rosemarie M, O’Hara M, O'Reilly E, Varadhachary G, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Mooij E, den Hertog E, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Teixeira M, Friesen K, De Wever W, Vanwijk R, Koops S, Keulemans J, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Teixeira M, Friesen K, De Wever W, Vanwijk R, Koops S, Keulemans J, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Teixeira M, Friesen K, De Wever W, Vanwijk R, Koops S, Keulemans J, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Teixeira M, Friesen K, De Wever W, Vanwijk R, Koops S, Keulemans J, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Teixeira M, Friesen K, De Wever W, Vanwijk R, Koops S, Keulemans J, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R, Bottinga Y, Cysique L, Guziu E, Tavera A, Te
50. Koppenol WH, Bounds PL and Dang CV: Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337, 2011.

51. Liu XS, Little JB and Yuan ZM: Otto Warburg’s Warburg effect to reverse Warburg effect; the new horizons of anti-cancer therapy. Med Hypotheses 144: 1102-1106, 2020.

52. Schneiderhan W, Scholer M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, Gress TM, Seufferlein T, Adler G and Oswald F: CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in vivo and ex vivo models. Gut 68: 1398-1408, 2019.

53. Lee SH, Hwang HK, Lee WJ and Kang CM: MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. Cell Oncol (Dordr) 44: 1363-1371, 2021.

54. Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, Maira SM, Moroni C, Lane HA and MM: Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep 25: 3047-3058.e4, 2018.

55. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verzax J, Tahhanini ZN, De Sahy D, Cadiou CJ, Kennedy KM, Diepart C, Jordan BF et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930-3942, 2008.

56. Wu DH, Liang H, Lu WN, Wang H, Su ZL, Zhang L, Ma JQ, Guo M, Tai S and Yu S: m--124 suppresses pancreatic ductal adenocarcinoma growth by regulating monocarboxylate transporter 1-mediated cancer cell lactate metabolism. Cell Physiol Biochem 50: 924-935, 2018.

57. Lai AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM et al: Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. Elife 9: e56782, 2020.

58. Koundourou N and Poulogiannis G: Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122: 4-22, 2020.

59. Alsulaiman A, Amin M, Piro F, Pizzuti L, Sebastiani V, Botti C, Mioni R, Zotti G and Tondo U: Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic cancer. Anticancer Res 27: 3519-3526, 2007.

60. Menendez JA and Lupu R: In support of fatty acid metabolism in cancer. Br J Cancer 122: 4-22, 2020.
92. Kasenda B, Bass A, Koebel D, Pestalozzi B, Borner M, Herrmann R, Jost L, Lobnig K, and Hess V: Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study. BMC Cancer 14: 728, 2014.

93. Anderson BC, Williams VG, Saito M, Bell J, Cade J, Cross AJ, King A, Riboli E, Sniehotta F, Treweek S, et al: Cancer prevention through weight control—where are we in 2020? Br J Cancer 124: 1049‑1056, 2021.

94. Jacobs EJ, Newton CC, Patel AV, Stevens VL, Islam F, Flinders W, and Gazumsk M: The association between body mass index and pancreatic cancer: Variation by age at body mass index assessment. Am J Epidemiol 189: 108‑115, 2020.

95. Chimento A, Casaburi I, Avena P, Trotta F, De Luca A, Rago V, Osmak M: Statins and cancer: Current and future prospects. Front Endocrinol (Lausanne) 9: 807, 2019.

96. Guillaumeletal F, Bidault G, Ouaissi M, Servais S, Gourvand V, Olives A, Lac S, Borge L, Roques J, Gayet O, et al: Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci USA 112: 2473‑2478, 2015.

97. Nam GH, Kwon M, Jung H, Ko E, Kim SA, Choi Y, Song SJ, Fang F, He X, Deng H, Chen Q, Lu J, Spraul M and Yu Y; Urayama S, Zou W, Brooks K, and Tolstikov V: Comprehensive lipidomics, and multi‑omics. Sci Adv 7: eabh2724, 2021.

98. Butera A, Roy M, Zampieri C, Mammarella E, Panatta E, Melino G, D'Alessandro A and Amelio I: p53‑driven lipidome discrimination of metabolic profiles of pancreatic cancer from normal tissue. Cancer Biochem 45: 1064‑1069, 2012.

99. Osmak M: Statins and cancer: Current and future prospects. Front Endocrinol (Lausanne) 9: 807, 2019.

100. Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Botto AJ, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang YP, Yu X, Bhatt V, Chiles E, Zhong H, et al: Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism. Cell Rep 29: 1287‑1298.e6, 2019.

101. Li T and Le A: Glutaminolysis in cancer. In: The Hexogonality of Cancer Metabolism. Le A (ed). Springer International Publishing, Cham, pp13‑32, 2018.

102. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh‑Chang N, et al: Glutamine supports pancreatic cancer growth through a KRAS‑regulated metabolic pathway. Nature 515: 496‑501, 2013.

103. Li L, Chen C, Jin Y, Wu K, Xu Z, Pan W, Zhong S, Wei Z, Nong T, et al: HIF‑2α regulates non‑canonical glutamine metabolism via activation of PFKmTORC2 pathway in human pancreatic ductal adenocarcinoma. J Cell Mol Med 21: 2896‑2908, 2017.

104. Raho S, Capobianco L, Malivindi R, Vozza A, Pizzolla C, De Leonardis F, Gorgoglione R, Scarcia P, Pezzuto F, Agrimi G, et al: KRAS‑regulated glutamine metabolism requires UCP2‑mediated aspartate transport to support pancreatic cancer growth. Nat Metab 2: 1373‑1381, 2020.

105. Yang S, Hwang S, Kim M, Seo SB, Lee JH and Jeong SM: Mitochondrial glutamine metabolism via GOTS2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis 9: 55, 2018.

106. Wise DR, Deberardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Lisin E, Yudkoff M, McMahon SB and Thompson CB: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782‑18787, 2008.

107. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendel JT and Dang CV: c‑Myc suppression of miR‑23a/b enhances mitochondrial glutaminolysis and glutamine metabolism. Nature 458: 762‑765, 2009.

108. Roux C, Riganti C, Borgogno SF, Curto R, Curcio C, Catanzaro V, Digilio G, Padovan S, Puccinelli MP, Isabello M, et al: Endogenous glutamine decrease is associated with pancreatic cancer progression. Oncotarget 8: 95361‑95376, 2017.

109. He J, Li F, Zhou Y, Hou X, Liu S, Li X, Zhang Y, Jing X and Yang L: LncRNA XLOC_006390 promotes pancreatic carcinogenesis and glutamine metabolism by stabilizing c‑Myc. Cancer Lett 469: 419‑428, 2020.

110. Lowman KH, Hanse EA, Yang Y, Ishak Gaba MB, Tran TQ, Li H and Kong M: p53 Promotes cancer cell adaptation to glutamine deprivation by upregulating SLC7A3 to increase arginine uptake. Cell Rep 26: 3051‑3060.e4, 2019.

111. Tajan M, Hock AK, Blagih J, Robertson NA, Labuschagne CF, Kruiswijk F, Hump Ton JJ, Adams PD and Vouven HD: A role for GOTS in the glutaminolysis of the novel oncogenic strategies through the expression of SLC1A3. Cell Metab 28: 721‑736.e6, 2018.

112. Tran TQ, Lowman KH, Reid MA, Mendez‑Dorantes C, Pan M, Yang Y and Kong M: Tumor‑associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene 36: 1991‑2001, 2017.

113. Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutscher T, Kang Y, et al: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542: 119‑123, 2017.

114. Duyk A, Ramesh V and Lusale JW: The evolving metabolic landscape of chromatin biology and epigenetics. Nat Rev Genet 21: 737‑753, 2020.

115. Wang G and Han J: Connections between metabolism and epigenetic modifications in cancer. Med Rev 1: 199‑221, 2021.

116. Zechovsky JP and MacVicar T: Interplay between metabolism and epigenetics: A nuclear adaptation to environmental changes. Mol Cell 62: 695‑711, 2016.
133. Kottakas F, Nicolay BN, Rouanne A, Karmik R, Gu H, Nagle JM, Boukhali M, Hayward MC, Li YY, Chen T, et al: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 566: 390-395, 2019.

134. Wang H, Li QF, Chiu S, and Leung YC: Arginase deprivation inhibits pancreatic cancer cell migration, invasion and EMT via the down regulation of snail, slug, twist, and MMP1/9. J Physiol Biochem 76: 73-80, 2020.

135. Wang J, Yang S, He P, Schetter AJ, Gaedeke J, Ghadimi BM, Rich T, Yizhar Y, Lee DH, Gaidatzis MM, et al: Endothelial nitric oxide synthase transduction inducer (NOSTRIN) is a negative regulator of disease aggressiveness in pancreatic cancer. Clin Cancer Res 22: 5992-6001, 2016.

136. Herner A, Sauliuaita D, Michalski CW, Erkan M, De Oliveira T, Altmanová S, Aposposi I, Fries H and Kleef J: Glutamine increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer 129: 2349-2359, 2011.

137. Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Pifferi O IV and Alimonti DA: Dihydrothymoethene combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol Pharm 15: 369-376, 2018.

138. Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Herner A, Sauliuaita D, Michalski CW, Erkan M, De Oliveira T, Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Pifferi O IV and Alimonti DA: Dihydrothymoethene combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol Pharm 15: 369-376, 2018.

139. Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Maertin S, Elperin JM, Lotshaw E, Sendler M, Speakman SD, Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Herner A, Sauliuaita D, Michalski CW, Erkan M, De Oliveira T, Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Pifferi O IV and Alimonti DA: Dihydrothymoethene combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol Pharm 15: 369-376, 2018.

140. Kottakas F, Nicolay BN, Rouanne A, Karmik R, Gu H, Nagle JM, Boukhali M, Hayward MC, Li YY, Chen T, et al: LKB1 loss links serine metabolism to DNA methylation and tumorigenesis. Nature 566: 390-395, 2019.

141. Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell 61: 667‑676, 2016.

142. Saliakoura M, Sebastiano MR, Nikdima I, Pozzato C and Konstantinidou G: Restriction of extracellular lipids renders pancreatic cancer dependent on autophagy. J Exp Clin Cancer Res 124: 333‑344, 2021.

143. Malchiodi ZX, Cao H, Gay MD, Safronenka A, Bansal S, Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV and D’Haese JG: Metformin influences drug sensitivity in pancreatic cancer cell adaptation to environmental challenges. Am J Physiol Gastrointest Liver Physiol 313: G524-G536, 2017.

144. Maertin S, Elperin JM, Lotshaw E, Sendler M, Speakman SD, Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Herner A, Sauliuaita D, Michalski CW, Erkan M, De Oliveira T, Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Pifferi O IV and Alimonti DA: Dihydrothymoethene combined with a polyamine transport inhibitor is effective against gemcitabine resistant pancreatic cancer. Mol Pharm 15: 369-376, 2018.

145. Ashto TM, Gilles McKenna W, Kunz-Schughart LA and Higgins GS: Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 24: 2482-2490, 2018.

146. Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell 61: 667-676, 2016.

147. Lambert A and Brand M: Reactive oxygen species production by mitochondrial oxidize. Methods Mol Biol 554: 165-181, 2009.

148. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell 61: 667‑676, 2016.

149. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell 61: 667‑676, 2016.

150. Nevala-Plagemann C, Hidalgo M and Garrido-Laguna I: From Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Zong WX, Rabinowitz JD and White E: Mitochondria and cancer. Mol Cell 61: 667‑676, 2016.

151. Masoud R, Reyes-Castellanos G, Lac S, Garcia J, Dou S, Shurtleff LA, Abratt CD, Gao J, De Oliveira T, Altmanová S, Aposposi I, Fries H and Kleef J: Glutamine increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer 129: 2349-2359, 2011.

152. Cancedo A, Abraham L, Steinman L, Lerpriyapong K, Marcelli S, Cocco L, Ratti S, Folino MY, Murata RM, Rosalen PL, et al: Metformin influences drug sensitivity in pancreatic cancer cells. Adv Biol Regul 68: 13-30, 2018.
171. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and DeBerardinis RJF: Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481: 385-388, 2011.

172. Olives J, Mayers JR, Pourmand J, Rishchany V, Bursiewicz W, Antosik P, Grzanka D, Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B, Wei X, Ke Q, Sui X, Cai Z, Liang Y, Xing C, Wang H, Hu P, Li J, Huang W, Wang J and Jiang C: Cancer-associated adipocytes exhibit distinct phenotypes and facilitate tumor progression in pancreatic cancer. Oncol Rep 42: 2537-2549, 2019.

173. Meyer KA, Neeley CK, Baker NA, W ashabaugh AR, Flesher CG, Nelson BS, Frankel TL, Lumeng CN, Lyssiotis CA, Wynn ML, et al: Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer. Biochem Biophys Rep 7: 144-149, 2016.

174. Ye H, Zhong Q, Zheng S, Li G, Lin Q, Wei L, Fu Z, Zhang B, Li LZ, and Chen T: R-Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death Dis 9: 453, 2018.

175. Asencio-Bañón C, Defaminie N, Sáez JC, Mesnil M and Goyow AS: Direct intercellular communications and cancer: A snapshot of the biological roles of connexins in prostate cancer. Cancers (Basel) 11: 1370, 2019.

176. Luo M, Luo Y, Mao N, Huang G, Teng C, Wang H, Wu J, Liao X and Yang J: Cancer-associated fibroblasts accelerate malignant progression of non-small cell lung cancer via connexin 43-formed unidirectional gap functional intercellular communication. Cell Physiol Biochem 51: 335-336, 2018.

177. Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B, Wei X, Ke Q, Sai X, Wang Y, et al: Cell adhesion-mediated mitochondrial transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. J Hematol Oncol 11: 18, 2018.

178. Marlein CR, Paddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM and Rushworth SA: CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Res 79: 2285-2297, 2019.

179. Dowmark TH, Saccomano M, Hulikova A, Alves F and van de Stolpe A, Roelen B and Clevers HB (eds). Academic Press, Boston, pp299-328, 2021.

180. Lisakova A, Grousseau A, Bozorgmehr A, Grund C, Hauser M, Kuske S, Halayek M, Jay P, Giardino P, Mailler B, Bussolati G, Röcken M, Korzus E, Pfeifer L, Dobrovic A, Cossu M, and Dallapiccola B: The ever-changing landscape of pancreatic cancer stem cells. Cancer Res 74: 7309-7320, 2014.

181. Rausch V, Liu L, Apel A, Rettig T, Gladkikh J, Labsch S, Kalifatidis G, Kaczorowski A, Groth A, Gross W, et al: Autophagy mediates pancreatic cancer tumour-initiating cells in a hypoxic microenvironment. J Pathol 227: 325-335, 2012.

182. Zhu H, Wang D, Zhang L, Xie X, Wu Y, Liu Y, Shao G and Su Z: Upregulation of autophagy by hypoxia-inducible factor-1 promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep 32: 935-942, 2014.

183. Sainz B Jr, Martín B, Batra R, McMillan RH, Sainz B Jr, Martín B, Uesugi M, Yang J, et al: Bivalent metabolic disturbances synergistically contribute to pancreatic cancer stem cell maintenance. Cell Metab 27: 1741-1754, 2018.

184. Alcalá S, Sancho P, Alcala S, Hermann PC and Sainz B Jr: Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. JCI Insight 3: e99831, 2018.

185. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and DeBerardinis RJF: Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nat Commun 7: 10893, 2016.

186. Depeint F, Bruce WR, Changari N, Mehta R and O'Brien PJ: Mitochondrial function and toxicity: Role of the B vitamin family in mitochondrial energy metabolism. Chem Biol Interact 163: 94-112, 2006.

187. Rovira M, Scott SG, Liss AS, Jensen J, Thayer SP and Leach SD: Isolation and characterization of centrosinacular/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci USA 107: 75-80, 2010.

188. Sainz BJ Jr, Alcalá S, García E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, Tatari M, Miranda-Lorenzo I, Hidalgo M, Gomez-Lopez G, et al: Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its stem cell compartment. Gut 64: 1921-1935, 2015.

189. Li C, Wu JJ, Hyenes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliacca M and Simeone DM: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141: 2218-2227.e5, 2011.

190. Miranda-Lorenzo I, Dorado J, Lonardo E, Alcala S, Serrano AG, Clausell-Tormos J, Cioffi M, Megias D, Zagarac S, Balic A, et al: Intracellular autofluorescence: A biomarker for epithelial cancer stem cells. Nat Methods 11: 1161-1169, 2014.

191. Sancho P, Alcalá S, Usachov V, Hermann PC and Sainz B Jr: The ever-changing landscape of pancreatic cancer stem cells. Pancreatology 16: 489-496, 2016.

192. Pepe C, Jee J, Miao X, Su X, Vargas-Vega N, Gao C, Ota T, Srinivasan A, Cao Q, Zhang H, et al: Targeting arsenic pathway in pancreatic cancer stem cells promotes therapeutic benefit of CPI-613. Oncotarget 6: 31151-31163, 2015.

193. Brandi J, Dando I, Pozza ED, Biondani G, Elliott V, Park K, Fanelli G, Zolla L, Costello E, et al: Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. J Proteomics 150: 310-322, 2017.

194. McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentre S, Warrones MO, Word AE, Carrer A, Salz TH, Natsume Y, et al: Epigenomic reprogrammation during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet 49: 367-376, 2017.

195. Alcalá S, Sancho P, Martínez H, Navarro D, Pedrero C, Martin-Hijano L, Vivas E, Earl J, Rodríguez-Serrano M, Ruiz-Cañas L, et al: ISG15 and ISGylation is required for pancreatic cancer stem cell maintenance and plasticity. Nat Commun 11: 2682, 2020.

196. Nimmakayala RK, Leon F, Rachagani S, Rauth S, Nallasamy P, Marimuthu S, Shailendra GK, Chhonker YS, Chugh S, Chirraurvi R, et al: Metabolic programming of distinct cancer stem cell subpopulations promotes metastasis of pancreatic ductal adenocarcinoma. Cancer Discov 10: 219-231, 2021.

197. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D’Agostino R Jr, Warmoes MO, Word AE, Carrer A, Salz TH, Natsume Y, et al: Pancreatic cancer: Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 18: 695-707, 2017.

198. Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS and Van Cutsem E: A phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol 15: 3189-3196, 2019.